KRAS and colorectal neoplasm: MCLA-158, an LGR5 EGFR bispecific antibody, has therapeutic efficacy in preclinical models of various epithelial cancer types by inhibiting the growth of KRAS-mutant colorectal tumors, blocking metastasis initiation, and suppressing tumor expansion 31.